INTERFERON SYSTEM IN PATIENTS WITH CHRONIC DISEASES DURING IMMUNOMODULATING THERAPY

The analysis of interferon (IFN) I (α, β), II (γ) and III (λ) types by RT-PCR-RV, ELISA, the determination of the biological activity of IFN in the dynamics of the treatment of chronic immuno-mediated diseases with immunomodulating drugs. Different degrees of severity, reduced biological activity of IFN type I and II in chronic urogenital infections and bronchial asthma (BA) was corrected by using IFN inducers in basic therapy. In patients with asthma, an imbalance of RNA of IFN types I and III was detected. The inclusion of cycloferon reduced by 2.5 times the frequency of BA exacerbations during the year. As a result of treatment of patients with multiple sclerosis (MS) with recombinant IFNβ-1a for more than 12 months.there was a decrease in increased expression of IFN I genes and IFN II type proteins, stabilization of the neurological state. Thus, in chronic infections and BA, the deficiency and imbalance of IFN is compensated by the introduction of IFN inducers. In contrast, a decrease in elevated levels of IFN RNA in MS is achieved with prolonged administration of the recombinant drug IFNβ-1a, acting, possibly, on the basis of reverse regulation.